Amplia Therapeutics Ltd (ASX: ATX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Amplia Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $31.99 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 193.85 million
Earnings per share -0.029
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Amplia Therapeutics Ltd (ASX: ATX)
Latest News

ATX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Amplia Therapeutics Ltd

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

ATX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
21 Jan 2022 $0.17 $-0.01 -5.71% 137,572 $0.18 $0.18 $0.17
20 Jan 2022 $0.18 $0.01 6.06% 252,025 $0.18 $0.19 $0.18
19 Jan 2022 $0.17 $-0.01 -5.88% 220,009 $0.17 $0.17 $0.17
18 Jan 2022 $0.17 $0.00 0.00% 111,245 $0.17 $0.17 $0.17
17 Jan 2022 $0.18 $-0.01 -5.56% 91,958 $0.18 $0.18 $0.18
14 Jan 2022 $0.18 $0.00 0.00% 8,000 $0.18 $0.18 $0.18
13 Jan 2022 $0.18 $0.02 12.50% 215,795 $0.17 $0.19 $0.17
12 Jan 2022 $0.16 $-0.01 -6.06% 213,894 $0.16 $0.17 $0.16
11 Jan 2022 $0.17 $0.00 0.00% 90,403 $0.16 $0.17 $0.16
10 Jan 2022 $0.17 $0.01 6.25% 14,025 $0.16 $0.17 $0.16
07 Jan 2022 $0.16 $0.00 0.00% 68,362 $0.16 $0.16 $0.16
06 Jan 2022 $0.16 $0.00 0.00% 261,584 $0.16 $0.16 $0.16
05 Jan 2022 $0.16 $0.00 0.00% 61,507 $0.17 $0.17 $0.16
04 Jan 2022 $0.16 $-0.01 -6.06% 45,328 $0.16 $0.16 $0.16
31 Dec 2021 $0.17 $0.00 0.00% 4,132 $0.17 $0.17 $0.16
30 Dec 2021 $0.17 $0.01 6.45% 177,583 $0.16 $0.17 $0.16
29 Dec 2021 $0.16 $-0.01 -6.06% 250,486 $0.16 $0.16 $0.16
24 Dec 2021 $0.17 $0.00 0.00% 75,000 $0.17 $0.17 $0.17
23 Dec 2021 $0.17 $0.00 0.00% 2,929 $0.17 $0.17 $0.17

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
20 Dec 2021 S Jane Bell Buy 714 $103,571
On-market trade.
15 Dec 2021 Warwick Tong Issued 33 $5,666
Rights issue.
15 Dec 2021 Warwick Tong Issued 100 $18,000
Rights issue.
15 Dec 2021 Christopher Burns Issued 55 $9,999
Rights issue.
15 Dec 2021 Christopher Burns Issued 18 $3,148
Rights issue.
15 Dec 2021 John Lambert Issued 55 $9,900
Rights issue.
15 Dec 2021 John Lambert Issued 32 $5,850
Rights issue.
15 Dec 2021 John Lambert Issued 29 $4,958
Rights issue.
15 Dec 2021 Robert Peach Issued 110 $18,867
Rights issue.
15 Dec 2021 Robert Peach Issued 332 $59,931
Rights issue.
15 Dec 2021 S Jane Bell Issued 69 $12,472
Rights issue.
15 Dec 2021 S Jane Bell Issued 72 $12,340
Rights issue.
15 Dec 2021 S Jane Bell Issued 148 $26,726
Rights issue.
02 Sep 2021 S Jane Bell Buy 557 $115,432
On-market trade.
01 Sep 2021 S Jane Bell Buy 36 $6,890
On-market trade.
07 Jun 2021 John Lambert Issued 130 $20,150
Exercise of options.
07 Jun 2021 John Lambert Exercise 130 $20,150
Exercise of options. As per announcement on 08/06/2021.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Andrew John Cooke Company Secretary Oct 2013
Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
Dr John Lambert Chief Executive OfficerManaging Director Jun 2019
Dr Lambert has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, John was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry John was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). John is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
Dr Robert Peach Non-Executive Director Sep 2015
Dr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos Limited, becoming Chief Scientific Officer and raising US$59M in venture capital and US$800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for US$7.8B. Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is currently on the Board of Directors of AdAlta Pty Limited and Rekover Therapeutics, and serves on the Scientific Advisory Board of Eclipse Bioinnovations. Robert is the co-author of 70 scientific publications and book chapters, and 26 patents and patent applications.
Ms S Jane Catherine Bell Non-Executive Director Apr 2021
Ms Bell is a non-executive director with more than 30 years' experience in law firms, financial services and corporate treasury operations gained living in Melbourne, London, Toronto, San Francisco and Brisbane. Jane has been a non-executive director since 2002, serving on 12 boards including nine health and medical research boards. Jane currently serves as Deputy Chair of Monash Health, Director of Jessie McPherson Private Hospital, Chair of the Community Advisory Group of the Melbourne Genomics Health Alliance and is a Member of the Administrative Appeals Tribunal. Jane is a former Chair of Melbourne Health (Royal Melbourne Hospital), Chair of Biomedical Research Vic, Deputy Chair of Westernport Water Corporation, Director of UCA Funds Management, WorkSafe Victoria, Hudson Institute of Medical Research-Monash Institute of Medical Research-Prince Henry's Institute of Medical Research, Queensland Institute of Medical Research Trust, Australian Red Cross (Qld) and Victorian Women's Housing Association.
Dr Warwick Bonner Tong Non-Executive DirectorNon-Executive Chairman May 2018
Dr Tong is a NZ trained physician with more than 25 years experience in the Pharmaceutical and Biotechnology industry. After his early career in General Medical Practice Warwick has held a wide variety of roles in the pharmaceutical and biotech industry in NZ(Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx - Cancer Therapeutics CRC). Warwick currently serves as director of Aculeus Therapeutics Pty Ltd, CannaPacific Pty Ltd and its affiliate e3D Pharma Pty Ltd. He is a member of the Strategic Advisory Board of the Maurice Wilkins Centre in Auckland NZ and of the CSIRO Manufacturing Business Advisory Committee. Warwick is a former CEO and director of CTx, director and Chair of the CTx commercialisation company, CTxONE, and director and Chair of BioMedVic.
Dr Christopher John Burns Non-Executive Director May 2018
Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 25 years. After completing a PhD in Organic Chemistry at the University of Melbourne Chris undertook post-doctoral studies in the USA before moving to Pfizer UK, where he worked on a variety of drug discovery projects. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry. Chris then moved to the Melbourne-based biotech as Head of Medicinal Chemistry and later as Research Director. During this time he led teams in the discovery of two anti-cancer agents that have entered clinical trial, including the drug momelotinib which successfully completed Phase III studies. Most recently Chris was a Laboratory Head at the Walter and Eliza Hall Institute of Medical Research in Melbourne and currently holds executive roles with privately held biotechs MecRx, Certa Therapeutics and OccuRx. Dr Burns is the inventor on over 30 patents and a co-author on over 50 scientific publications.
Jeff Carter Chief Financial Officer
Mark Devlin Chief Science Officer
Rhiannon Jones Director Operations

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 20,374,618 16.32%
Bond Street Custodians Limited <Lam1 D08047 A/C> 8,750,000 7.01%
Citicorp Nominees Pty Limited 5,803,803 4.65%
BNP Paribas Noms Pty Ltd <Drp> 4,595,985 3.68%
Ctxt Pty Ltd 4,514,468 3.62%
Elk River Holdings Pty Ltd 2,942,142 2.36%
Christopher John Burns 2,472,243 1.98%
Warwick Tong 2,355,140 1.89%
34Th Avenue Pty Ltd <Devlin Family A/C> 2,215,237 1.77%
Gp Securities Pty Ltd 1,930,000 1.55%
Mr Andrew Podolak 1,925,000 1.54%
Mark Sullivan <Aems Consulting A/C> 1,661,428 1.33%
Cancer Research Technology Limited 1,360,524 1.09%
HWH Power Pty Ltd <Hwh Super Fund A/C> 1,270,000 1.02%
Merrill Lynch (Australia) Nominees Pty Limited 1,058,057 0.85%
Cofactor Llc 1,000,000 0.80%
Swanmark Super Pty Ltd <Rc Swan Super Fund A/C> 1,000,000 0.80%
Ravinna Pty Ltd <Ravinna A/C> 993,992 0.80%
Mr Michael Andrew Whiting and Mrs Tracey Anne Whiting <Whiting Family S/F A/C> 940,000 0.75%
Margaret Frame 923,016 0.74%